Indexed on: 25 Jan '17Published on: 25 Jan '17Published in: The Journal of Urology®
It is unknown whether urinary biomarkers for prostate cancer (PCa) have added utility to clinical risk calculators in different racial groups.Examine the added utility to clinical risk calculators for urinary biomarkers in prediction of PCa in African American (AA) and non-AA men.Demographics, Prostate Cancer Prevention Trial (PCPT) risk scores, biomarker data (PCA3 and T2ERG), and biopsy pathology features prospectively collected from 718 men as part of the Early Detection Research Network (EDRN).Utility determined by generation of receiver operating curves and comparison of area under the curve (AUC) values for the baseline multivariable PCPT model and for models containing biomarker scores.PCA3 and T2ERG added utility for prediction of PCa and clinically significant PCa (CS PCa) when combined with PCPT risk calculator. This utility was seen in non-AA men only (PCA3: AUC 0.64 increased to 0.75 for PCa [p<0.001], 0.69 to 0.77 for CS PCa p<0.001; T2ERG: 0.64 to 0.74 for PCa [p<0.001], 0.69 to 0.73 for CS PCa [p=0.029]). AA men did not have added benefit with addition of biomarkers (PCA3: AUC 0.75 to 0.77 [p=0.64], 0.65 to 0.66 [p = 0.74]; T2ERG: 0.75 to 0.74 [p = 0.74], 0.65 to 0.64 [p = 0.88], for PCa and CS PCa, respectively).include small number of AA men (n= 72). Post-hoc, sub-group analysis nature limits findings to being hypothesis generating.As novel biomarkers are discovered, clinical utility should be established across demographically diverse cohorts.